Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.

about

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.

Item

http://www.wikidata.org/entity/Q47402625

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Palliative chemotherapy and ta ...... troesophageal junction cancer.

@en

Palliative chemotherapy and ta ...... troesophageal junction cancer.

@nl

type

Item

label

Palliative chemotherapy and ta ...... troesophageal junction cancer.

@en

Palliative chemotherapy and ta ...... troesophageal junction cancer.

@nl

prefLabel

Palliative chemotherapy and ta ...... troesophageal junction cancer.

@en

Palliative chemotherapy and ta ...... troesophageal junction cancer.

@nl

P1476

Palliative chemotherapy and ta ...... stroesophageal junction cancer

@en

P2093

Ate van der Gaast

http://www.w3.org/2001/XMLSchema#string

Ewout W Steyerberg

http://www.w3.org/2001/XMLSchema#string

Manon Cw Spaander

http://www.w3.org/2001/XMLSchema#string

Marco J Bruno

http://www.w3.org/2001/XMLSchema#string

Ron Hj Mathijssen

http://www.w3.org/2001/XMLSchema#string

Vincent T Janmaat

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus

Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction

Chemotherapy for advanced gastric cancer

Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction

Chemotherapy for metastatic carcinoma of the esophagus and gastric cardia

What is "quality of evidence" and why is it important to clinicians?

Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

P304

CD004063

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1002/14651858.CD004063.PUB4

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ernst J Kuipers

Maikel P Peppelenbosch

P577

2017-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29182797

http://www.w3.org/2001/XMLSchema#string

P932

6486200

http://www.w3.org/2001/XMLSchema#string